|
Published by: Global Markets Direct
Published: Dec. 26, 2012 - 40 Pages
Table of Contents- Introduction
- Global Markets Direct Report Coverage
- Rhinovirus Infection Overview
- Therapeutics Development
- An Overview of Pipeline Products for Rhinovirus Infection
- Rhinovirus Infection Therapeutics under Development by Companies
- Rhinovirus Infection Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Rhinovirus Infection Therapeutics – Products under Development by Companies
- Rhinovirus Infection Therapeutics – Products under Investigation by Universities/Institutes
- Companies Involved in Rhinovirus Infection Therapeutics Development
- Discovery Laboratories, Inc.
- Clarassance, Inc.
- Rhinovirus Infection – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- lucinactant - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- lucinactant LS - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- dexamethasone beloxil - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Rhinovirus Infection Therapeutics – Drug Profile Updates
- Rhinovirus Infection Therapeutics - Dormant Products
- Rhinovirus Infection – Product Development Milestones
- Featured News & Press Releases
- May 05, 2010: Discovery Lab's Surfaxin LS Improves Pulmonary Function And Reduces Lung Inflammation In Established Model Of RDS
- May 05, 2009: Discovery Labs’ Surfaxin Significantly Improves Lung Surfactant Distribution In Preclinical RDS Model
- May 31, 2007: Discovery Laboratories, Inc Announced Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published In Pediatrics
- May 18, 2005: Discovery Laboratories, Inc Announced New Data of Surfaxin Survival Benefit Continues Through One Year Of Life
- Feb 14, 2005: Discovery Labs Receives Approvable Letter From FDA For Surfaxin For Respiratory Distress Syndrome In Premature Infants
- Feb 02, 2005: INO Therapeutics Entered Into Agreement With Forest Laboratories To Co-Promote Infasurf
- Sep 14, 1998: Forest Laboratories Infasurf Found To Infringe Abbott's Survantas Patents
- Jul 17, 1995: Forest Laboratories Announced FDA Response To Infasurf Meeting
- May 17, 1995: Forest Laboratories Announced FDA Action On Infasurf
- Mar 14, 1995: Forest Laboratories Submittted New Drug Application For Infasurf For The Treatment Of Respiratory Distress Syndrome
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Rhinovirus Infection, H2 2012
- Products under Development for Rhinovirus Infection – Comparative Analysis, H2 2012
- Number of Products under Development by Companies, H2 2012
- Number of Products under Investigation by Universities/Institutes, H2 2012
- Comparative Analysis by Late Stage Development, H2 2012
- Comparative Analysis by Mid Clinical Stage Development, H2 2012
- Comparative Analysis by Early Clinical Stage Development, H2 2012
- Products under Development by Companies, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- Discovery Laboratories, Inc., H2 2012
- Clarassance, Inc., H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
- Rhinovirus Infection Therapeutics – Drug Profile Updates
- Rhinovirus Infection Therapeutics – Dormant Products
- List of Figures
- Number of Products under Development for Rhinovirus Infection, H2 2012
- Products under Development for Rhinovirus Infection – Comparative Analysis, H2 2012
- Products under Development by Companies, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- Late Stage Products, H2 2012
- Mid Clinical Stage Products, H2 2012
- Early Clinical Stage Products, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Route of Administration, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Molecule Type, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
AbstractRhinovirus Infection – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Rhinovirus Infection - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Rhinovirus Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rhinovirus Infection. Rhinovirus Infection - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Rhinovirus Infection.
- A review of the Rhinovirus Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Rhinovirus Infection pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Rhinovirus Infection.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Rhinovirus Infection pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports,
company profiles and country profiles from over 720 research firms. Our reports will
provide you with the critical business and competitive intelligence you need for strategic planning and marketing
research. Coverage includes the US, UK, Europe, Asia and global markets.
|
